Evidence map›Paper›PMID 35720727›Full record

ArticleFrontiers in neuroscience2022

Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer's Disease.

Tina E Brinkley, Iris Leng, Thomas C Register, Bryan J Neth, Henrik Zetterberg, Kaj Blennow, Suzanne Craft

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02984540 (Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02984540 nacompletednot on this map

Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease

TypeinterventionalSponsorWake Forest University Health SciencesRan2015 to 2017Enrolled25ConditionsMild Cognitive Impairment, Insulin ResistanceArmsLow-Carbohydrate Diet, Low-Fat Diet
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Tina E BrinkleyDepartment of Internal Medicine, Section on Gerontology and Geriatric Medicine, Winston-Salem, NC, United States.
Iris LengDivision of Public Health Sciences, Department of Biostatistics and Data Sciences, Winston-Salem, NC, United States.
Thomas C RegisterDepartment of Pathology/Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States.
Bryan J NethDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
Suzanne CraftDepartment of Internal Medicine, Section on Gerontology and Geriatric Medicine, Winston-Salem, NC, United States.
Mayo Clinic in Arizona · USNorth Carolina Division of Public Health · USSahlgrenska University Hospital · SEUniversity of Gothenburg · SEWake Forest University · US

Funding

Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Wake Forest Alzheimer's Disease Core CenterP30AG049638 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI RAPP, STEPHEN R · 2016 to 2020
$12.2M
NCATS NIH HHS UL1 TR001420NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG072947
6 · The paper itself

Abstract

Background: Ketogenic diets have been used to treat both obesity and neurological disorders, including epilepsy and more recently Alzheimer's disease (AD), likely due to favorable effects on both central and peripheral metabolism. Improvements in body composition have also been reported; however, it is unclear if diet-induced changes in adiposity are related to improvements in AD and related neuropathology. Purpose: We examined the effects of a Modified Mediterranean Ketogenic (MMK) diet vs. an American Heart Association (AHA) diet on body weight, body composition, and body fat distribution and their association with cerebrospinal fluid (CSF) biomarkers in older adults at risk for AD. Methods: Twenty adults (mean age: 64.3 ± 6.3 years, 35% Black, 75% female) were randomly assigned to a crossover trial starting with either the MMK or AHA diet for 6 weeks, followed by a 6-week washout and then the opposite diet for 6 weeks. At baseline and after each diet adiposity was assessed by dual-energy x-ray absorptiometry and CSF biomarkers were measured. Linear mixed effect models were used to examine the effect of diet on adiposity. Spearman correlations were examined to assess associations between adiposity and CSF biomarkers. Results: At baseline there was a high prevalence of overweight/obesity and central adiposity, and higher visceral fat and lower peripheral fat were associated with an adverse CSF biomarker profile. The MMK and AHA diets led to similar improvements in body composition and body fat distribution. Significant correlations were found between changes in adiposity and changes in CSF biomarkers (r's = 0.63-0.92, p's < 0.05), with notable differences by diet. Decreases in body fat on the MMK diet were related to changes in Aβ biomarkers, whereas decreases in body fat on the AHA diet were related to changes in tau biomarkers and cholinesterase activity. Interestingly, increases in CSF Aβ on the MMK diet occurred in those with less fat loss. Conclusion: An MMK diet leads to favorable changes in body composition, body fat distribution, and CSF biomarkers. Our data suggest that modest weight loss that maximizes visceral fat loss and preserves peripheral fat, may have the greatest impact on brain health. Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT02984540].

Indexed as

adiposityCSF biomarkersketogenic dietmild cognitive impairmentprediabetessubjective memory complaints

Identifiers

PMID35720727
PMCPMC9202553
OpenAlexW4281770774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.